Efficacy of Remifentanil in Preventing Emergence Agitation

Launched by SAGLIK BILIMLERI UNIVERSITESI GAZI YASARGIL TRAINING AND RESEARCH HOSPITAL · Aug 1, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether a medication called remifentanil can help prevent a condition known as emergence agitation in patients undergoing rhinoplasty, a type of nose surgery. Emergence agitation is a state of confusion or agitation that some patients experience when waking up from anesthesia. The study is comparing the effectiveness of remifentanil to other pain relief medications, fentanyl and nitrous oxide (N2O), in patients who receive desflurane for anesthesia.

To participate in this trial, individuals must be over 18 years old and scheduled for rhinoplasty, and they should be classified as ASA I or II, which means they are generally healthy or have mild health issues. The study is currently looking for participants, and those who join can expect to undergo standard procedures related to their surgery, while their responses to the different pain relief methods will be closely monitored. It’s important to note that certain individuals, such as those with specific allergies or severe health conditions, will not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study included patients over the age of 18, planned to undergo rhinoplasty by the plastic and reconstructive surgery department, and American Society of Anesthesiologist (ASA) I-II.
• • -
• Exclusion Criteria:
• • Patients with a known history of allergy to the drugs to be administered in the study, ASA III and above, body mass index (BMI) 35\>kg/m2, younger than 18 years of age, any problems that would prevent general anesthesia in the preoperative evaluation (upper respiratory tract infection, etc.), and those who did not agree to participate in the study were excluded from the study.